Diet-based therapies like CDED + PEN may help control Crohn’s symptoms and improve nutrition without adding medications. This study suggests some adults can maintain remission and gain nutritional benefits over a year...

This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemistry and Biophysics Reports.

People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...

This trial tests a new oral drug (Alpha-0261) for moderate-to-severe ulcerative colitis and could matter to people who haven’t responded to standard medicines. Early-phase studies mainly assess safety but also collect...

The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...

New drugs in mid-stage trials may expand treatment options for people with moderate to severe Crohn's disease, especially those who have not responded to existing therapies. This trial is measuring clinical remission at...

EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...

FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.

People with Crohn’s disease may benefit from research that identifies the specific genes and immune pathways driving inflammation — this study points to over 100 genes in gut ILC3 cells that could explain how genetic...

Shorter height at IBD diagnosis was more common in Hispanic/Latino children and those without private insurance, which may reflect inequities in timely diagnosis and access to nutrition and care—issues that can affect...

The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...

This review summarizes evidence on robotic surgery for IBD, which could affect surgical choices and expectations about recovery and risks for patients needing colorectal or pelvic operations. It suggests robotic...

FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...

This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.

The appendix in conventional UC appears to be inflamed early and then remodels to fibrous obliteration over decades, which could influence thinking about timing or rationale for appendectomy-based interventions.

Krill oil improved colitis signs and intestinal barrier markers in a mouse model and changed colon gene expression linked to cell adhesion—findings that may interest people tracking dietary or supplemental approaches for...

Older adults with UC face different risks and treatment trade-offs than younger patients — higher infection and cancer risks, medication toxicities, and challenges with diagnosis and colonoscopy. Understanding these...

The study links a common environmental pollutant (UV-328) to worsened experimental colitis and altered cholesterol metabolism, suggesting environmental exposures might influence IBD activity and could point to new...

MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...

Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...

Cure8 found this source from Digestive diseases and sciences, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Community and awareness. Open the original article for the full...

Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from firstwordpharma.com.

Identifying simple features at diagnosis that predict a disabling 5‑year course could help patients and clinicians plan monitoring and treatment intensity earlier after Crohn’s diagnosis.

If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....

Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...

The review suggests that allergic-type (type 2) immune pathways may play a meaningful role in some people with Crohn's disease, which could point to new treatment options that target IgE, Th2 cytokines, epithelial...

New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...

High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...

A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...

Cure8 found this source from grandviewresearch.com, but the page could not be read reliably yet. It is tagged for Fistula and Procedures and surgery. Open the original article for the full details.

A commonly used probiotic, E.

This review suggests SSRIs and SNRIs may influence both brain and gut pathways relevant to symptom burden in IBD and DGBI — potentially improving mood, pain, motility, and aspects of inflammation. That could matter for...

The study identifies Gardenia-derived pectic polysaccharides that reduced inflammation and restored colon health in a mouse colitis model, suggesting a possible microbiome-mediated protective effect relevant to IBD...

The study explores a multi-herb formula that the authors report reduces inflammation and alters gut microbiota in a mouse model of ulcerative colitis, suggesting possible biological mechanisms worth further study.

The study identifies macrophage-derived microvesicles as modulators of intestinal barrier function and ER stress in ulcerative colitis models, suggesting a new mechanism that could be relevant to mucosal healing...

If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...

A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.

This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...

This study could validate a noninvasive stool-test strategy (FIT + fecal calprotectin) to triage which long-standing UC patients need colonoscopy, potentially improving surveillance efficiency and adherence.

People with IBD may have a higher-than-expected rate of biopsy-confirmed celiac disease in this Northern Indian cohort, and standard anti-tTG blood tests can be falsely positive in IBD. Confirmatory duodenal biopsy is...

This study suggests plant-derived exosome-like nanoparticles from a traditional herbal decoction may reduce inflammation, oxidative stress, and alter gut microbiota in a mouse model of colitis — an early preclinical step...

AI could help standardize endoscopic and histologic scoring in IBD, speed capsule endoscopy interpretation, and improve lesion detection — changes that might affect monitoring and diagnosis workflows for people with...

This study suggests erythritol — a common non-nutritive sweetener — may worsen experimental colitis and depression-like behavior in mice via microbiome and metabolic changes, raising questions about how ultra-processed...

Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Cureus.

People with IBD may face higher-than-expected rates of hypertensive disorders in pregnancy; identifying predictors could help target monitoring and preventive strategies. The study suggests prior HDP and gestational...

Cure8 could only read part of this source from bignewsnetwork.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Access, cost, and policy.

This study suggests that in IBD (and other diseases) the gut microbiome may lose long-associated symbionts and shift toward larger-genome, metabolically flexible microbes—an evolutionary perspective that could help...